Mortato E, Talamonti M, Marcelli L, Megna M, Raimondo A, Caldarola G, Bernardini N, Balato A, Campanati A, Esposito M, Bonifati C, Lora V, Potestio L, Lembo S, Loconsole F, De Luca E, Skroza N, Buononato D, Bianchelli T, Fargnoli MC, Tommasino N, Foti C, De Simone C, Bianchi L, Galluzzo M

Psoriasis: Targets and Therapy 2025, 15:455-469

Published Date: 16 September 2025

Review

Epidemiology of Hypertension in Psoriasis: An Analysis of Trends from 2006 to 2023

Zhang M, Chen JL, Fan SW, Sun XY, Zhou YQ, Luo Y, Wang J, Wang CX, Lin NX, Liu L, Li X

Psoriasis: Targets and Therapy 2025, 15:443-453

Published Date: 27 August 2025

Original Research

Machine Learning-Driven Prediction Models for Brodalumab Therapeutic Effect and Response Speed in Plaque Psoriasis

Peng L, Wang L, Chen L, Shen Z

Psoriasis: Targets and Therapy 2025, 15:429-442

Published Date: 21 August 2025

Review

The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome

Tang L, Bi H, Lin K, Chen Y, Xian H, Li Y, Xie H, Zheng G, Wang P, Chen Y, Yang B, Tan Y, Song Q, Wang M, Li G, Chang J, Guan Y, So KF, Lu C

Psoriasis: Targets and Therapy 2025, 15:411-428

Published Date: 18 August 2025

Review

Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis

Gisondi P, Bellinato F, Curic T, Girolomoni G

Psoriasis: Targets and Therapy 2025, 15:401-410

Published Date: 18 August 2025

Original Research

Causal Effect of Plasma Fatty Acid Profiles on Psoriasis Risk: Genetic Evidence from a Mendelian Randomization Study

Yao L, Wang X, Lu D, Tian S

Psoriasis: Targets and Therapy 2025, 15:389-399

Published Date: 16 August 2025

Original Research

Beyond Skin Clearance: Personalized Strategies for DLQI Improvement in Psoriasis -Insights From a Shanghai Prospective Cohort

Ma X, Xu Q, Kuai L, Shen F, Duan Z, Gao X, Zhang R, Wang R

Psoriasis: Targets and Therapy 2025, 15:373-387

Published Date: 13 August 2025

Original Research

TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses

Dai B, Tang Y, Zhang B, Xu G, Zhang Y, Ze K

Psoriasis: Targets and Therapy 2025, 15:361-372

Published Date: 12 August 2025

Review

Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis – A Comprehensive Literature Review

Al Alshaikh SA, Almarhoon ZM, Momattin H, Aleid M, Almousa ZH, Alqaisum AK, Mobarki FI, Almakki SA, Alturfi H, Almajed KJ

Psoriasis: Targets and Therapy 2025, 15:351-360

Published Date: 5 August 2025

Original Research

Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years

Mastorino L, Dapavo P, Burlando M, Gisondi P, Maronese CA, Ruggiero A, Galluzzo M, Pisani MC, Sacchelli L, Caldarola G, Avallone G, Marzano AV, Megna M, Campione E, Loconsole F, Bardazzi F, De Simone C, Quaglino P, Ribero S

Psoriasis: Targets and Therapy 2025, 15:339-350

Published Date: 4 August 2025

Original Research

Utilization and Costs of Laboratory Monitoring in Biological and Non-Biological Psoriasis Treatment – Large-Scale Claims Data Analysis

Wagner JN, Hagenström K, Müller KS, Stephan B, Augustin M, von Kiedrowski R

Psoriasis: Targets and Therapy 2025, 15:327-338

Published Date: 5 August 2025

Case report

Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis

Xiao Y, Sun J

Psoriasis: Targets and Therapy 2025, 15:321-325

Published Date: 23 July 2025

Review

Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach

Xu JM, Wu C, Feng H, Jin HZ

Psoriasis: Targets and Therapy 2025, 15:301-320

Published Date: 19 July 2025

Original Research

Psoriasis Does Not Seem to Impair Glomerular and Tubular Function – The Comprehensive Study on Serum and Urine

Nowowiejska J, Baran A, Hermanowicz JM, Sieklucka B, Koper-Lenkiewicz OM, Kamińska J, Pawlak K, Pawlak D, Flisiak I

Psoriasis: Targets and Therapy 2025, 15:285-299

Published Date: 18 July 2025

Original Research

Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany – Methodology and Outcomes of Claims Data Analysis

Hagenström K, Müller K, Ben-Anaya N, Augustin M

Psoriasis: Targets and Therapy 2025, 15:273-283

Published Date: 15 July 2025

Original Research

Tobacco Smoking Was Positively Associated with Disease Relapse at week 24 and 48 Among Patients with Psoriasis Vulgaris in Shanghai: A Prospective Study

Shen F, Ding Y, Qiang Y, Duan Z, Xu Q, Gao X, Zhang R, Wang R

Psoriasis: Targets and Therapy 2025, 15:261-272

Published Date: 14 July 2025

Original Research

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study

Mrowietz U, Sommer R, Gerdes S, Reguiai Z, Weger W, Daudén E, Maul JT, Ghislain PD, Laws PM, Naldi L, De Jong E, Mburu S, Koscielny V, Massana E, Domenech A, Gaarn du Jardin K, Kasujee I, Augustin M

Psoriasis: Targets and Therapy 2025, 15:243-259

Published Date: 28 June 2025

Original Research

Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience

Bertoli C, Torres T, Romita P, Stingeni L, Hansel K, Mastorino L, Ortoncelli M, Panzone M, Cruz MJ, Bianchi L, Zangrilli A, Musumeci ML, Micali G, Gerbino C, Simonetti O, De Simoni E, Longo C, Mahé E, Di Lernia V

Psoriasis: Targets and Therapy 2025, 15:233-241

Published Date: 28 June 2025

Original Research

Evolution of Drug Supply for Psoriasis from 2010 to 2022 – Real-World Claims Data Analysis in Germany

Hagenström K, Klinger T, Stephan B, Augustin M

Psoriasis: Targets and Therapy 2025, 15:221-231

Published Date: 27 June 2025

Original Research

Acupoint Injection Combined with BCG-PSN and Thymosin Enteric-Coated Tablets Improve China Han Psoriasis Vulgaris by Regulating T Cell Subsets

Li J, Zhao X, Pan H, Duan Y, Li W, Zhao Y, Yao L, Zhang K

Psoriasis: Targets and Therapy 2025, 15:209-220

Published Date: 19 June 2025

Original Research

Are Systemic Drug Choices for Psoriasis by Dermatologists Compatible with Psoriatic Arthritis? Data from the German National Psoriasis Registry PsoBest

Sorbe C, Kargin S, von Kiedrowski R, Thaci D, Weyergraf A, Blome C, Augustin M, Stephan B

Psoriasis: Targets and Therapy 2025, 15:197-207

Published Date: 30 May 2025

Original Research

Pediatric Pustular Psoriasis in Southern China: A 12-Year Retrospective Analysis of 41 Cases Focusing on Clinical Characteristics and Treatment Outcomes

Tang J, Hou Z, Liao W, Wang Y, Zhang G, Luo Y, Gao X, Wei Z

Psoriasis: Targets and Therapy 2025, 15:185-195

Published Date: 12 May 2025

Review

Challenges Psoriasis and Its Impact on Quality of Life: Challenges in Treatment and Management

Ponikowska M, Vellone E, Czapla M, Uchmanowicz I

Psoriasis: Targets and Therapy 2025, 15:175-183

Published Date: 1 May 2025

Original Research

Predictors of Quality of Life in Psoriasis Patients: Insights from a Cross-Sectional Study

Walniczek P, Ponikowska M, Kolarczyk EB, Spaleniak P, Mróz-Kijowska K, Czapla M, Uchmanowicz I

Psoriasis: Targets and Therapy 2025, 15:163-174

Published Date: 24 April 2025

Case report

Dual Biologic Therapy for Psoriasis in a Patient with Atopic Dermatitis

Ma L, Chen X, Aziz MAA, Chen A, Cai T, Chen S

Psoriasis: Targets and Therapy 2025, 15:159-161

Published Date: 23 April 2025

Original Research

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events

Fratton Z, Bighetti S, Bettolini L, Maione V, Arisi M, Buligan C, Stinco G, Errichetti E

Psoriasis: Targets and Therapy 2025, 15:145-158

Published Date: 11 April 2025

Review

Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy

Mateu-Arrom L, Puig L

Psoriasis: Targets and Therapy 2025, 15:127-144

Published Date: 11 April 2025

Original Research

Psoriasis: Prevalence, Clinical Variants and Quality of Life, Among Patients Attending the Skin Clinic at Mbarara Regional Referral Hospital, Uganda

Lubwama H, Mulyowa GK, Mirembe SK, Katungi TJ, Male M

Psoriasis: Targets and Therapy 2025, 15:117-126

Published Date: 2 April 2025

Original Research

Analysis of the Reduction in the Duration of Sick Leave for 32,512 Psoriasis Patients Following the Integration of Targeted Therapies for Psoriatic Disease into the Brazilian Healthcare System: a Retrospective Cohort Study

D’Almeida LFV, Duarte GV, Godinho MP, Cariello LH, Sousa GJB, Gomes CM

Psoriasis: Targets and Therapy 2025, 15:105-116

Published Date: 28 March 2025

Original Research

Treatment With Schistosoma Japonicum Peptide SJMHE1 and SJMHE1-Loaded Hydrogel for the Mitigation of Psoriasis

Liu X, Wang S, Jiang Y, Luo X, Yang Y, Huo L, Ye J, Zhou Y, Yang Z, Du F, Dong L, Mao C, Wang X

Psoriasis: Targets and Therapy 2025, 15:85-104

Published Date: 27 March 2025

Original Research

Treatment of Psoriasis with II-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of Secukinumab vs Ixekizumab in Real-World Practice

Lam J, Cazzaniga S, Seyed Jafari SM, Maul JT, Feldmeyer L, Bossart S, Yawalkar N, Heidemeyer K

Psoriasis: Targets and Therapy 2025, 15:71-84

Published Date: 27 March 2025

Case Series

Acrodermatitis Continua of Hallopeau and Generalised Pustular Psoriasis: Case Reports of Two Different Manifestations of IL36RN Mutation in Siblings

Gu M, Huang H, Xiao Z, Meng F, Sheng H, Lin Z, Li C, Wu Y

Psoriasis: Targets and Therapy 2025, 15:67-70

Published Date: 26 March 2025

Clinical Trial Report

A Randomized Controlled Trial for the Optimal Implementation of Psoriasis Treatment by Integrating Chinese and Western Medicine

Yu Y, Sun X, Hu R, Xia P, Wei Y, Yang W, Huang N, Ding Y, Guo S, Yang C, Weng H, Zhang Y, Ding X, Huang Q, Zhou X, Li X, Li B

Psoriasis: Targets and Therapy 2025, 15:55-66

Published Date: 21 March 2025

Original Research

Metagenomics Analysis of Altered Gut Microbiome in Psoriasis and the Mediation Analysis: A Case-Control Study

Xiao Y, Jing D, Xiao H, Mao M, Kuang Y, Shen M, Lv C, Jian X, Peng C, Chen X

Psoriasis: Targets and Therapy 2025, 15:45-54

Published Date: 19 March 2025

Original Research

Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis

Krefting F, Scheib C, Benson S, Hölsken S, Placke JM, Wedemeyer H, Sondermann W

Psoriasis: Targets and Therapy 2025, 15:29-44

Published Date: 1 March 2025

Case report

Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report

Christov S, Ohm F, Augustin M, Wagner JN

Psoriasis: Targets and Therapy 2025, 15:23-28

Published Date: 21 January 2025

Clinical Trial Report

Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients

Hölsken S, Krefting F, Mühlhaus S, Bese D, Schedlowski M, Sondermann W

Psoriasis: Targets and Therapy 2025, 15:9-22

Published Date: 10 January 2025

Original Research

Breakthrough Psoriasis in Patients Receiving Biologicals

Damsin T, Absil G, Libon F, Tassoudji N, Nikkels AF

Psoriasis: Targets and Therapy 2025, 15:1-8

Published Date: 3 January 2025